(Q72912401)
Statements
Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications (English)
Physiologic Observations in a Controlled Clinical Trial of the Antiemetic Effectiveness of 5, 10, and 15 mg of Δ9-Tetrahydrocannabinol in Cancer Chemotherapy. Ophthalmologic Implications (English)
1 reference
A. Wilson
D. Bowman
S. Kemel
G. Krepart
V. Marks
H. Schipper
G. Thomson
B. Weinerman
R. Weinerman
1 August 1981
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference